{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:16:47Z","timestamp":1790543807680,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.clinthera.2009.02.012","type":"journal-article","created":{"date-parts":[[2009,3,19]],"date-time":"2009-03-19T07:45:18Z","timestamp":1237448718000},"page":"272-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study"],"prefix":"10.1016","volume":"31","author":[{"given":"Louis-Georges","family":"Ste-Marie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Beary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Matzkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn M.","family":"Darbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur J.","family":"Racewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2009.02.012_bib1_1","unstructured":"National Osteoporosis Foundation. Osteoporosis fast facts [NOF Web site]"},{"key":"10.1016\/j.clinthera.2009.02.012_bib2_1","unstructured":"National Osteoporosis Foundation. Medications to prevent & treat osteoporosis [NOF Web site]"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2009.02.012_bib3","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2005.12.019","article-title":"Improving compliance and persistence with bisphosphonate therapy for osteoporosis","volume":"119","author":"Emkey","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2009.02.012_bib4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib5","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib6","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib7","first-page":"408","article-title":"Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT study","volume":"72","author":"Eastell","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.02.012_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00198-007-0531-9","article-title":"Monthly dosing of 75 mg risedronate on 2 consecutive days a month: Efficacy and safety results","volume":"19","author":"Delmas","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2009.02.012_bib13_1","unstructured":"US Dept of Health and Human Services. International Conference on Harmonisation; Guidance on General Considerations for Clinical Trials"},{"key":"10.1016\/j.clinthera.2009.02.012_bib14","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.284.23.3043","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2009.02.012_bib15_1","unstructured":"World Heath Organization. World Health Organization definitions for osteoporosis [WHO Web site]"},{"key":"10.1016\/j.clinthera.2009.02.012_bib16_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA)"},{"key":"10.1016\/j.clinthera.2009.02.012_bib17","series-title":"Tietz Textbook of Clinical Chemistry","year":"1999"},{"key":"10.1016\/j.clinthera.2009.02.012_bib18","first-page":"1895","article-title":"Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial BMD-MN Study Group","volume":"85","author":"Fogelman","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2009.02.012_bib19","series-title":"Statistical Methods","first-page":"374","author":"Snedecor","year":"1989"},{"key":"10.1016\/j.clinthera.2009.02.012_bib20","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo- controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2009.02.012_bib21","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2009.02.012_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: A prospective randomized, placebo-controlled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.clinthera.2009.02.012_bib23","first-page":"1906","article-title":"Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease","volume":"83","author":"Singer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2009.02.012_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","article-title":"Paget's disease of bone: Reduction of disease activity with oral risedronate","volume":"22","author":"Hosking","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2009.02.012_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2009.02.012_bib26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2009.02.012_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002239900584","article-title":"Risedronate, a highly effective, short-term oral treatment for Paget's disease: A dose-response study","volume":"64","author":"Brown","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.clinthera.2009.02.012_bib28","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1185\/030079907X242665","article-title":"Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: A 6-month pilot study","volume":"23","author":"Racewicz","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2009.02.012_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","article-title":"Efficacy of risedronate on clinical vertebral fractures within six months","volume":"20","author":"Roux","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2009.02.012_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","article-title":"Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis","volume":"74","author":"Harrington","year":"2004","journal-title":"Calcif Tissue Int"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291809000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:06Z","timestamp":1758962886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291809000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S0149291809000551"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2009.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}